Helliwell, Philip S <br/><br/>
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.  [electronic resource] 

 -  RMD open  02 2020 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2056-5933 
<br/><br/><label>Standard No.: </label>10.1136/rmdopen-2019-001149  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Arthritis, Psoriatic--complications<br/>Case-Control Studies<br/>Female<br/>HLA-B27 Antigen--drug effects<br/>Humans<br/>Injections, Subcutaneous<br/>Interleukin-12--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Physicians--statistics & numerical data<br/>Placebos--administration & dosage<br/>Spondylitis--drug therapy<br/>Tumor Necrosis Factor Inhibitors--administration & dosage<br/>Ustekinumab--administration & dosage